Abstract
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease-related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Clinical Lipidology |
Vol/bind | 16 |
Udgave nummer | 5 |
Sider (fra-til) | e77-e95 |
ISSN | 1933-2874 |
DOI | |
Status | Udgivet - 2022 |